Phase II trial to assess the efficacy of Iressa (gefitinib) 500 mg/day in patients with breast cancer who have failed tamoxifen or have an oestrogen receptor negative tumour and would be considered for systemic therapy

Trial Profile

Phase II trial to assess the efficacy of Iressa (gefitinib) 500 mg/day in patients with breast cancer who have failed tamoxifen or have an oestrogen receptor negative tumour and would be considered for systemic therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2008

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 02 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top